Bright Minds Biosciences
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
19 Vestry St, New York, New York, 10013,...Phone Number
(647) 407-2515Website
www.brightmindsbio.comRevenue
$5.3 MillionStock Symbol
DRUGIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bright Minds Biosciences
Founded in 2017, Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.Explore more
Bright Minds Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bright Minds Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Bright Minds Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Bright Minds Biosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Bright Minds Biosciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Bright Minds Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Bright Minds Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at Bright Minds Biosciences
Earning: See what the market has to say on Bright Minds Biosciences recently announced quarterly report
Check if Bright Minds Biosciences has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Bright Minds Biosciences
Compare insights from companies similar to Bright Minds Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bright Minds Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bright Minds Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bright Minds Biosciences.
Bright Minds Biosciences financials insights
Gather financial insights about Bright Minds Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$35M
Bright Minds Biosciences Tech Stack
A closer look at the technologies used by Bright Minds Biosciences
See more technologies
Most Recent Scoops
Project
reported that its Phase II study of BMB-101 in treatment-resistant Absence seizures demonstrated a 73.2% decrease in seizure frequency and a 74% reduction in area-under-the-curve seizure burden, measured via ambulatory EEG in a refractory patient population on multiple concurrent medications.
Pharmaceuticals
Project
Bright Minds Biosciences has estimated the patient population for each of its BMB-101 indications Absence seizures and DEEs at approximately 250,000 to 300,000 patients, with orphan epilepsy pricing precedents in the mid-hundreds of thousands of dollars per patient representing a potential market in the tens of billions of dollars.
Project
Bright Minds Biosciences has highlighted that FINTEPLA (fenfluramine) carries a list price of approximately $96,000 per year with an average realized price closer to $200,000 per year due to weight-based dosing, supporting the pricing rationale for BMB-101 given the large treatment-refractory population across both its target indications.
Project
Bright Minds Biosciences has noted that video EEG serves as the primary endpoint for its Phase III Absence seizure study, providing an objective and quantifiable measure of seizure activity, with placebo effect expected to be approximately 15–20% on adverse events but not on seizure counts, and near-zero placebo seizure activity observed in Phase II.
Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Bright Minds Biosciences News & Media
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bright Minds Biosciences
Sign Up For FreeTo access detailed company insights
Founded in 2017, Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resist... Read More
